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ISSUES WITH INSULIN PUMP
Offi ce staff at an endocrinology practice were asked to see a patient who was having a mysteriously low blood glucose while receiving insulin using a Medtronic MiniMed Revel portable infusion pump. The pump allows information to be downloaded, and it showed that the patient was getting boluses during the night. The patient vehemently denied administering any doses. The data showed that up to 10 units at a time were being administered. It was suspected that the patient leaned over onto the pump while sleeping, putting enough pressure on the activation system that a dose was released.
We asked Medtronic about this incident, and the company told us it has received rare reports of people accidently rolling over onto the pump at night and activating a bolus. A patient would have to activate 2 buttons for the pump to actually deliver a dose, which is why this is a rare occurrence. There is a feature to lock out the keypad so that this does not happen. The patient was shown how to use the keypad, and the problem was resolved. A second patient also had mysteriously low blood glucose levels while using the Revel pump. In this case, the patient was entering erroneous information into pump software. The pump has a bolus dosing "wizard" that allows patients to enter their blood glucose and the amount of carbohydrate grams they've eaten. The patient was accidentally entering the measured blood glucose into the carbohydrate fi eld instead of the number of carbohydrates eaten. For example, 220 was entered in the carbohydrate fi eld instead of 60 g.
The safest way to administer a bolus dose is to use the glucose meter that goes with the pump. This automatically communicates the glucose level information to the pump so the user does not need to manually enter the results. In this case, the patient's insurance did not cover the test strips for this pump, so the patient was using his own glucose meter and entering the results manually. The pump will warn you when an entry is outside the usual range, but the warning can be overridden. In this case, the patient could not see the pump screens clearly, because the backlight lighting is quite dim. Medtronic told us there is no way to make the light any brighter. They agreed to pass on the information from this report internally to consider whether any enhancements were needed to improve the device.
FUTURE DEVICES FOR U-500 INSULIN
In response to questions we posed to Eli Lilly about the availability of a dedicated U-500 device for the company's U-500 insulin, a Lilly representative confi rmed that 2 projects are underway in an effort to meet the needs of patients using U-500 insulin. Lilly is working to develop a prefi lled pen designed to deliver Humulin R U-500 (insulin human), and the company is also working with a development partner on the design of a dedicated U-500 insulin syringe. These dedicated devices, if approved, will allow administration of Humulin R U-500 in actual units without dose conversion to nondedicated syringe markings (unit markings with a U-100 insulin syringe or volume [mL] markings with a volumetric syringe).
Due to the complexity and risks inherent in device development and regulatory review, Lilly is unable to speculate on the timing of availability of these devices. Until then, Humulin R U-500 must be administered using a U-100 insulin syringe or a volumetric (tuberculin or allergy) syringe.
PATIENTS NEEDED TESTING AFTER PEN MISUSE
Once again, a US hospital must contend with the fact that thousands of the hospital's patients may have received an insulin injection from an insulin pen previously used for another patient (http://newyork. cbslocal.com/2014/03/11/l-i-hospital-reused-insulinpen-part-may-mean-hepatitis-hiv-risk-for-patients/).
In this recent event, patients are being notifi ed of possible transmission of blood-borne pathogens and being told they should be tested for hepatitis and human immunodefi ciency virus (HIV), although the risk is low. No actual cases of disease transmission have been tied to any of the previous "outbreaks" we've published. However, there is strong evidence that retrograde travel of blood carrying hemoglobin, red blood cells, and squamous cells into the pen cartridge occurs after injection (http://www.ajhp. org/content/70/14/1244.abstract?sid=ff9dab0f-4fe9-47c5-be85-bea86bc25ab0). So it won't be surprising if transmission is eventually documented.
In this latest case, one of the nurses at the hospital said she believed that reusing insulin pen reservoirs on multiple patients was an acceptable practice. This problem is well known and not easily overcome with employee education and ongoing monitoring. Patients should be educated to not accept their insulin injection from an insulin pen unless they see their name on an attached label.
DIASTAT ACUDIAL REQUIRES SETTING AND LOCKING OF THE DOSE
The Diastat Acudial (diazepam rectal gel) delivery system is available for rectal administration to manage selected refractory epilepsy patients who are on stable regimens of anti-epileptic drugs and also require intermittent use of diazepam to control bouts of increased seizure activity (cluster seizures). The product is available in 10 mg or 20 mg rectal syringes designed to deliver minimum dosages of 5 mg or 12.5 mg, respectively, with dosage increments of 2.5 mg up to a maximum of either 10 mg or 20 mg. (There is also a 2.5 mg syringe available for pediatrics.) There are 2 unlocked rectal syringes per package.
Since the introduction of the device, a number of errors have occurred because the device was not properly dialed and locked prior to administration. This led to the administration of too much medication. Some of these errors have resulted in respiratory depression requiring emergency intervention. Before the product is dispensed, syringes must be dialed, set, and locked to the prescribed dose by the pharmacist, even when the maximum dose is pre-scribed. Once set and locked, the prescribed dose will appear in the dose display window, and the locking ring, designated with a green "ready" band, will be engaged. This helps to prevent the wrong dose or an overdose from being administered by the caregiver.
Managers should reinforce the need for pharmacists to lock the syringes and educate patients and caregivers about the proper use of the device, including confi rming that the prescribed dose is visible in the display window; the green ready band is visible; and the smaller rectal tip size is used if the patient is a child. A 2007 US Food and Drug Administration Patient Safety News video (produced in cooperation with ISMP) on proper use of Diastat is available at: http://www.accessdata.fda.gov/psn/transcript. cfm?show=59#7.
